UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/654,761	09/04/2003	Dennis Ausiello	17509-0065	6913
	7590 01/23/200 D ASBILL & BRENN	EXAMINER		
999 PEACHTR	EE STREET, N.E.		MACNEILL, ELIZABETH	
ATLANTA, GA 30309			ART UNIT	PAPER NUMBER
			3767	<u> </u>
SHORTENED STATUTORY	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
3 MO!	NTHS	01/23/2007	PAPER	

# Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Application No.	Applicant(s)			
		10/654,761	AUSIELLO ET AL.			
	Office Action Summary	Examiner	Art Unit			
	•	Elizabeth R. MacNeill	3767			
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status		•				
2a)□	2a) ☐ This action is <b>FINAL</b> . 2b) ☑ This action is non-final.					
Dispositi	on of Claims					
5)⊠ 6)⊠ 7)□ 8)□ <b>Applicati</b> 9)□ 10)□	Claim(s) 1-10,12-21,24,27,28,32 and 34-36 is/34a) Of the above claim(s) is/are withdraw Claim(s) 1-10,12-21,24,27 and 32 is/are allowed Claim(s) 28 and 34-36 is/are rejected.  Claim(s) is/are objected to.  Claim(s) are subject to restriction and/or are subject to restriction and/or are specification is objected to by the Examine The drawing(s) filed on is/are: a) accept a comparison of the drawing are subjected to by the Examine The drawing of the correct that any objection to the drawing are subjected to by the Examine The oath or declaration is objected to by the Examine Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Examine The oath or declaration is objected to b	wn from consideration. ed.  r election requirement.  r.  epted or b) objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is objected.	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)  1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date  4) Interview Summary (PTO-413) Paper No(s)/Mail Date  5) Notice of Informal Patent Application 6) Other:						

Application/Control Number: 10/654,761

Art Unit: 3767

### **DETAILED ACTION**

This action is in response to applicant's arguments submitted 1 December 2006.

## Claim Rejections - 35 USC § 103

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. Claim 28 is rejected under 35 U.S.C. 103(a) as being unpatentable over Santini (US 5,797,898) in view of Cheikh (US 5,660,846) and Barnard et al (US 6,204,390) Santini teaches an implantable device for controlled delivery of a therapeutic substance comprising a substrate, a plurality of reservoirs, a release system, and control means for releasing the medicament in the reservoirs (Fig 5). Santini does not disclose the delivery of parathyroid hormone, but does disclose that a generic hormone could be delivered from the device (Col 5). Cheikh teaches the delivery of a parathyroid hormone from an implantable device (Col 7). It would have been obvious to one of ordinary skill in the art at the time the invention was made to choose the parathyroid hormone to deliver from the device of Santini in order to provide appropriate medical treatment to the patient.

Santini also fails to disclose the use of a blood plasma calcium sensor, but does disclose that "biosensors" may be coupled with his device (abstract). Barnard et al discloses a blood plasma calcium sensor designed to be implanted in the body (Col 33).

1. It would have been obvious to one of ordinary skill in the art at the time the invention

Art Unit: 3767

was made to choose the calcium sensor for the device of Santini in order to provide appropriate medical treatment to the patient.

3. Claims 34-36 are rejected under 35 U.S.C. 103(a) as being unpatentable over Santini in view of Cheikh.

Santini teaches an implantable device for controlled delivery of a therapeutic substance comprising a substrate, a plurality of reservoirs, a release system, and control means with wires to and from each reservoir for releasing the medicament in the reservoirs (Fig 5). Santini does not disclose the delivery of parathyroid hormone, but does disclose that a generic hormone could be delivered from the device (Col 5). Cheikh teaches the delivery of a parathyroid hormone from an implantable device (Col 7). It would have been obvious to one of ordinary skill in the art at the time the invention was made to choose the parathyroid hormone to deliver from the device of Santini in order to provide appropriate medical treatment to the patient.

## Allowable Subject Matter

4. Claims 1-10, 12-21, 24,27, and 32 are allowed.

### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth R. MacNeill whose telephone number is (571)-272-9970. The examiner can normally be reached on 7:00-3:30pm M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kevin Sirmons can be reached on (571)272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

**ERM** 

Mary Will

KEVIN C. SIRMONS

TONT EVAMINER